Minimal residual disease in colorectal cancer — Update after ASCO-GI 22: Dr. Kopetz

Table of contents: 

00:48: Overview of the talk
1:17: Minimal residual disease in CRC — Possible how?
2:38: CTCs versus ctDNA
3:00: Different kinds of ctDNA tests
3:43: Why are ctDNA MRD tests exciting?
4:45: What is minimal residual disease (MRD)?
6:30: CtDNA status post surgery
8:30: Single test versus serial tests
9:28: Different scenarios post-treatment
10:26: Currently available tests
11:08: CIRCULATE-Japan results
13:50: DFS by CtDNA dynamics
14:47: CtDNA clearance after adj chemo
15:43: Clinical utility of ctDNA MRD testing
16:40: COBRA Stage II colon cancer ctDNA trial
16:50: CIRCULATE US trial for early stage III colon cancer
19:08: DYNAMIC-III trial
20:06: Clinical utility: Trials for new curative intent treatments
22:27: BioNTech personalized vaccine trial for ctDNA+ patients
24:19: CtDNA MRD testing allows new kinds of trial design
26:32: Proof of principle MRD pilot trials
28:25: Resources for people interested
29:03: INTERCEPT Program at MDA
29:46: FAQ: How to interpret test results?
32:40: FAQ: Quick primer on survival curves
35:15: FAQ: Interval between ctDNA positivity & results on imaging
36:30: FAQ: Can a ctDNA+ status change without treatment?
37:43: FAQ: What does negative ctDNA test status over time mean?
38:50: FAQ: Can the ctDNA+ test tell where the cancer is hiding?
39:37: FAQ: I’m ctDNA+, should I start the next line treatment now?
42:10: FAQ: Is ctDNA MRD testing useful with resected peritoneal disease?
44:28: Conclusions
46:55-59:05 Q&A